Otsuka adds Phase 3 detail behind Voyxact in IgA nephropathy

Otsuka’s Phase 3 VISIONARY update on Voyxact gives the company a stronger evidence package behind one of the newest entrants in IgA nephropathy. The headline result is familiar but still important: in a prespecified interim analysis of the ongoing trial, sibeprenlimab delivered a 51.2% placebo-adjusted reduction in 24-hour urine protein-to-creatinine ratio at nine months, reinforcing the dataset that underpinned the drug’s FDA accelerated approval in November 2025. (pubmed.ncbi.nlm.nih.gov)

The background matters here. IgA nephropathy is a chronic, progressive kidney disease driven by abnormal IgA biology, and proteinuria remains a key marker of risk for progression. Otsuka first announced positive interim VISIONARY topline data in October 2024 and said at the time that final kidney function results were expected in early 2026. FDA later granted accelerated approval to Voyxact for reducing proteinuria in adults with primary IgA nephropathy at risk for progression, while explicitly noting that long-term slowing of kidney function decline has not yet been established. (otsuka-us.com)

The newly published interim analysis fills in the details. According to the NEJM report, VISIONARY randomized 510 adults with biopsy-confirmed IgA nephropathy to subcutaneous sibeprenlimab 400 mg every four weeks or placebo for 100 weeks. The interim efficacy analysis included 320 patients who had the opportunity to complete the month-nine visit. At that point, proteinuria fell 50.2% in the sibeprenlimab arm and rose 2.1% in the placebo arm. Biomarker findings also moved in the expected direction, with APRIL levels down 95.8% and pathogenic galactose-deficient IgA1 down 67.1% at week 48. Serious adverse events during treatment were reported in 3.5% of sibeprenlimab-treated patients and 4.4% of placebo-treated patients, with no deaths reported. (pubmed.ncbi.nlm.nih.gov)

Additional data presented at ISN WCN’26 extended the picture beyond proteinuria. In an exploratory analysis, 82.5% of patients receiving Voyxact versus 52.6% on placebo achieved negative microscopic hematuria, defined as 0 to 5 red blood cells per high-power field, by 48 weeks. Median time to reach that threshold was 9 weeks with sibeprenlimab and 24 weeks with placebo. Those findings do not change the regulatory basis of approval, but they add another signal that APRIL blockade may be affecting disease activity in ways clinicians care about. The same conference update also reiterated that the study continues to evaluate kidney function preservation using eGFR slope over a 24-month treatment period.

Mechanistically, Voyxact is notable because it targets APRIL, a cytokine viewed as a key driver in the IgA nephropathy cascade. Otsuka and its subsidiary Visterra have positioned the therapy as a potentially disease-modifying approach rather than a purely supportive one. That framing is consistent with the biomarker data, and the exploratory hematuria findings point in the same direction, though it remains an inference until kidney function outcomes mature. (otsuka-us.com)

Otsuka executives have emphasized that point in prior statements. In the company’s 2024 trial update, chief medical officer John Kraus said the interim data suggested APRIL targeting could offer “a new therapeutic strategy” for people with this progressive kidney disease, while Visterra CEO Brian Pereira described the program as a potentially disease-modifying option. Those comments came before approval, but they help explain why the VISIONARY readout has drawn attention in a competitive IgA nephropathy market that now includes multiple mechanistic approaches and increasing investor scrutiny of proteinuria versus eGFR outcomes. (otsuka-us.com)

Why it matters: For veterinary professionals, this is primarily a translational signal rather than a practice-changing development. Still, it’s a useful one. Immune-mediated kidney disease remains an area where comparative medicine can inform how clinicians think about biomarkers, mechanism-based therapy, and the gap between surrogate endpoints and durable organ protection. VISIONARY shows a targeted biologic can generate a large proteinuria effect with a placebo-like serious adverse event profile in the interim dataset, and the newer hematuria analysis adds another potentially relevant marker of response. But regulators are still requiring proof that the drug changes the course of kidney decline. That distinction will feel familiar to anyone following renal therapeutics across species. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next real test is the 24-month eGFR slope endpoint from the ongoing blinded Phase 3 study. FDA has already tied continued approval to confirmatory evidence of long-term clinical benefit, and Otsuka has said those data are intended to support traditional approval. If the kidney function readout is positive, Voyxact could move from promising surrogate-driven launch to a more firmly established disease-modifying therapy in IgA nephropathy. (fda.gov)